profit from every $100 of sales.
$0$100
InterCure
$3.91+8.61% today
-44.5% in 1 year
1-year low $3.301-year high $7.25
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What InterCure sold, what it kept, and what it did with the cash.
Sales went from ₪389 million in 2022 to ₪270 million in 2025, with -₪35.7 million of profit last year.
SalesProfit
InterCure vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| InterCure | No profit yet | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads InterCure's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of ILS | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 389 | 356 | 239 | 270 | |
| 155 | 105 | 30 | 33 | |
| 41 | 38 | -45 | 7 | |
| 70 | -24 | -51 | -7 | |
| 45 | -62 | -68 | -36 | |
| 0.99 | -1.36 | -1.48 | – | |
| 39.9% | 29.6% | 12.7% | 12.3% | |
| 10.6% | 10.6% | -18.9% | 2.5% | |
| 11.5% | -17.4% | -28.4% | -13.2% |
Balance sheet
| In millions of ILS | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 958 | 787 | 763 | 691 |
| Cash | 233 | 101 | 78 | 46 |
| Total debt | 255 | 196 | 211 | 183 |
| Total liabilities | 437 | 330 | 365 | 294 |
| 501 | 455 | 397 | 397 | |
| 45 | 46 | 46 | – | |
| 6.1% | -4.5% | -8.7% | -3.3% | |
| 8.9% | -13.6% | -17.1% | -9.0% |
Cash flow
| In millions of ILS | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 51 | -54 | -67 | 17 | |
| 20 | 3 | 4 | 4 | |
| 32 | -56 | -71 | 13 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| 9 | 3 | 2 | 2 |
Valuation
- –
- –
- –
- 0.3×
- 0.6×
- 12.1×
- –
- 8.3%
- -22.2%
- 0.0%
Profitability
- 12.3%
- 2.5%
- -13.2%
- -17.4%
- -4.8%
- -4.0%
- -8.8%
- -5.3%
- -7.0%
- 0.2%
Growth
- −11.4%
- –
- +118.6%
- –
- +10.2%
Financial health
- –
- 0.46
- 26.5%
- -7.4×
- 1.48
- 0.97
- 0.27
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 28%of 958
Bottom 31%of 888
Bottom 7%of 889
Top 11%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2025 | -0.22 | – | – |
| Oct 3, 2024 | 0.03 | – | – |
| Aug 30, 2024 | 0.00 | – | – |
| May 1, 2024 | 0.00 | – | – |
| Mar 29, 2024 | 0.05 | – | – |
| Dec 26, 2023 | 0.05 | – | – |
| Aug 31, 2023 | 0.03 | 0.05 | −40.0% |
| May 15, 2023 | 0.01 | 0.08 | −87.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
58No pass
Philip Fisher
18No pass
Peter Lynch
24No pass
Joel Greenblatt
0No pass
Charlie Munger
13No pass
Terry Smith
10No pass
Questions about InterCure
Is InterCure a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the InterCure AI analysis
What does InterCure do?
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. It is in Drug Manufacturers - Specialty & Generic.
Does InterCure pay a dividend?
No. InterCure does not pay a dividend at the moment.
Is InterCure stock halal?
No. InterCure does not pass our halal screen: its debt is 114% of its market value, at or above the 33% limit. How we check
How has InterCure stock done over the past year?
Down 44.5% over the past twelve months, to $3.91. It traded between $3.30 and $7.25 and is 46.1% below its high.
Who are InterCure's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with InterCure's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.